Tandem Diabetes Care stock came into this earnings season on a tear, with the shares already sharply higher over the past month. Today the move turned into a jolt, as the stock jumped another 19% to US$22.38 after the Q2 print. The headline is clear: revenue reached US$254.56m and the company again reported a loss, yet investors locked on to one thing.

The market is treating margin repair as the story that matters. Gross margin reached 57%, one of the highest levels Tandem Diabetes Care has recorded, and that is what traders rewarded.

Is Tandem Diabetes Care now a clear bargain on 1.5x P/S, or could rising losses still justify a discount? See how today’s move lines up against the fundamentals in our valuation analysis for Tandem Diabetes Care

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$254.56m vs. US$240.68m (up about 6%)
• Net Loss, Q2 2026 vs. Q2 2025: US$21.17m loss vs. US$52.40m loss (loss narrowed about 60%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.31 loss per share vs. US$0.78 loss per share (loss per share narrowed about 60%)
• Gross Margin, Q2 2026 vs. Q2 2025: 57% vs. about 52% (expanded about 5 percentage points)

Prefer clean charts instead of scrolling through dense earnings tables and margin figures? Get a complete visual view of Tandem Diabetes Care's business, with an easy-to-scan focus on its valuation and how the stock is being priced today, in our company report for Tandem Diabetes Care.

Tandem Diabetes Care bull case gets margin proof

Bulls argue Tandem Diabetes Care can turn pharmacy PayGo, international direct sales and new products into a higher margin, more recurring model. Q2 gives concrete support. Revenue grew about 6% while worldwide pump shipments rose about 10%, which implies supplies revenue was held back by infusion set shortages rather than weak demand. Gross margin reached 57%, up about 5 percentage points year on year and close to company best levels, while operating expenses stayed roughly flat at US$159m. That supports the claim of operating leverage. Pharmacy PayGo moved to about 10% of US sales with around 45% formulary coverage, and international pumps grew about 19% with direct launches underway in multiple countries. New technology is moving forward, with Mobi tubeless submitted to the FDA and the AIDANET closed loop study cleared to start.

Bear concerns on losses and risk are only partly eased

Bears worry that rising losses, heavy investment and competitive and reimbursement pressure will keep Tandem Diabetes Care from sustainable profitability. Q2 narrows that concern but does not remove it. The company still reported a net loss of US$21.17m, even with a 3% adjusted EBITDA margin and reduced stock based compensation. Cash and investments declined from US$570m to US$456m after the Roche settlement, CRM build and an equity investment, which shows the cost of the current playbook. Pharmacy PayGo is only about 10% of U.S. sales and management admits near term revenue headwinds when pumps move into that channel. International expansion depends on flawless execution while infusion set constraints already hurt supplies revenue. The latest print softens fears around margin direction, but execution and capital allocation risk remain central to the bear case.

Compare Tandem Diabetes Care’s margin repair story and international growth ambitions, and see how institutions are reacting. See the consensus price target analysis for Tandem Diabetes Care

Stay Ahead With Simply Wall St

If Tandem Diabetes Care’s margin repair and international push have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a setup that fits your entry plan. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the key updates that matter for your holdings. For a broader view, tap into the Community to see how other investors are thinking about similar risks and opportunities. By spotting potential catalysts and pressure points early, you give yourself a better chance to stay ahead of the market rather than reacting after the fact.

Seeking Alternatives Beyond Tandem Diabetes Care

Fresh ideas move fast. Some stocks are already building momentum, others are dropping into attractive ranges. Scan these under the radar lists before the crowd catches up and get in early.

• Spot resilient trends early by checking companies with strong balance sheets and fundamentals through the list of solid balance sheet and fundamentals stocks (49 results)
• Ride potential breakout themes by reviewing curated nuclear infrastructure opportunities in the 89 nuclear energy infrastructure stocks
• Track powerful income ideas by scanning a focused set of high yield payers in the 8 dividend fortresses

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.